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PENILAIAN KESAN ANTI-HIPERTENSI DAN VASORELAKSASI
EKSTRAK PHALERIA MACROCARPA
ABSTRAK
Kajian ini menyiasat kesan anti-hipertensi ekstrak Phaleria macrocarpa pada tikus
hipertensi spontan (SHR),  tikus Wistar Kyoto (WKY) dan kesan ekstrak terhadap
vasorelaksasi di dalam cincin aortik terasing  dari pada tikus Sprague Dawley
menggunakan pendekatan bioaktiviti. Buah kering telah diekstrak secara
berperingkat dengan pelarut-pelarut yang berkepolaran berbeza. Kesan anti-
hipertensi terhadap beberapa peringkat dos ekstrak telah dinilai dengan
menggunakan kaedah tekanan darah sistolik bukan invasif. Ekstrak eter petroleum
(PE) dan ekstrak air (WE) menurunkan tekanan darah pada hari ke-14 (15.9 dan
27.7% masing-masing, p<0.05), menunjukan kedua-dua ekstrak mempunyai kesan
aktiviti anti-hipertensi. WE menurunkan kedua-dua tekanan arteri purata (MAP)
dan kadar denyutan jantung (HR) pada tikus WKY sebanyak 16.3 dan 4.3%
masing-masing (p<0.05). WE menghalang peningkatan aruhan-norepinefrina (NE)
terhadap MAP dan HR dalam WKY dengan mengurangkan kesan isoprenalina
terhadap tindak balas presor (p<0.05), mencadangkan ada kemungkinan terdapatnya
kesan antagonis-alfa dan penghalang saluran kalsium. WE merencat peningkatan
MAP, HR dan halaju gelombang denyutan (PWV) (p<0.05) dengan ketara. SHR
yang telah diberi secara oral selama 14 hari dengan WE menurunkan secara
signifikan tahap plasma enzim penukar angiotensin (p<0.05). Selain itu, ia juga
meningkatkan tahap plasma nitrik oksida (NO) dengan meyokong kesannya ke atas
PWV secara signifikan (p<0.05), memandangkan NO secara langsung
xxi
mengurangkan kekakuan arteri yang ditentukan oleh nilai PWV. Dalam kajian in
vitro, PE dan WE merencat pengecutan aruhan-NE pada cincin aortik tikus
sebanyak 40 dan 58% masing-masing (p<0.05). Fraksi aktif WE, WF-4
menunjukkan kesan vasorelaksasi yang besar (42.8%, p<0.05). Sub-fraksi SF-2 dari
fraksi WF-4 merencat pengecutan aorta tikus sehingga 44.5% (p<0.05). SF-2
menghasilkan kesan vasorelaksasi pada kedua-dua cincin aortik tanpa endotelium
dan dengan kehadiran endotelium. Walau bagaimanapun, inkubasi cincin aortik
dengan kehadiran endotelium, L-NAME dan indometasin menyekat kesan
vasorelaksasi SF-2 dengan ketara, menunjukkan penglibatan laluan NO dan
prostasiklin, masing-masing. Malahan, SF-2 didapati menunjukkan kesan
vasorelaksasi terhadap pra-pengecutan-NE dalam cincin aortaik tanpa kehadiran
endotelium melalui perencatan pengecutan aruhan kalsium di dalam larutan Kreb
bebas kalsium, mencadangkan sekatan influk kalsium melalui reseptor kendalian
(ROCC) saluran kalsium (p<0.05). Apabila dilakukan analisis kromatografi cecair
berprestasi tinggi (HPLC), SF-2 didapati mengandungi rutin, mangiferin dan asid
galik (0.04%, 0.21% dan 0.04% masing-masing). Kajian ini menyokong potensi
penggunaan ekstrak Phaleria macrocarpa untuk merawat hipertensi dalam
perubatan tradisional.
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EVALUATION OF ANTI-HYPERTENSIVE AND VASORELAXANT
EFFECTS OF PHALERIA MACROCARPA EXTRACTS
ABSTRACT
The present study investigated the anti-hypertensive effect of Phaleria macrocarpa
extracts in spontaneously hypertensive rats (SHR), Wistar Kyoto (WKY) rats and
the vasorelaxant effect of the extracts in isolated rat aorta of Sprague Dawley rats
using bioactivity guided approach. The dried fruits were extracted sequentially in
solvents with different polarity. The anti-hypertensive effect of the graded doses of
crude extracts was evaluated in SHR by non-invasive blood pressure method.
Petroleum ether (PE) and water extracts (WE) significantly reduced the blood
pressure on 14th day of treatment (15.9 and 27.7% respectively, p<0.05) suggesting
profound anti-hypertensive activity of these two extracts. WE reduced both the
mean arterial pressure (MAP) and heart rate (HR) in WKY by 16.3 and 4.3%
respectively (p<0.05). WE inhibited norepinephrine (NE) induced elevation of
MAP and HR in WKY with less effects against the pressor responses to
isoprenaline (p<0.05) suggesting its possible alpha-antagonistic and calcium
channel blocking effect. WE significantly inhibited MAP, HR and pulse wave
velocity (PWV) when compared with control group (p<0.05). An oral
administration of WE to SHR for 14 days significantly inhibited the plasma level of
angiotensin converting enzyme (p<0.05). Moreover, it elevated plasma nitric oxide
(NO) level with respect to control group (p<0.05) supporting its effect on PWV as
NO directly reduces the stiffness in arteries determined by the values of PWV. In
xxiii
the in vitro study, PE and WE inhibited NE induced contraction in rat aortic rings
by 40 and 58% respectively (p<0.05). The active WE fraction WF-4 showed
considerable vasorelaxant effect (42.8% relaxation, p<0.05). The sub-fraction SF-2
of WF-4 inhibited contraction in rat aorta up to 44.5% (p<0.05). SF-2 elicited
vasorelaxation in aortic rings with both denuded as well intact endothelium.
However, incubation of intact aortic rings with L-NAME and indomethacin
significantly blocked the vasorelaxant effect of SF-2, suggesting the involvement of
NO and prostacyclin pathway respectively. Moreover, SF-2 was found to exhibit its
vasorelaxant effect in denuded aortic rings pre-contracted with NE by inhibiting
calcium induced contraction in calcium free Kreb’s solution suggesting blockage of
calcium influx through receptor operated calcium channels (ROCC) (p<0.05).
When subjected to high performance liquid chromatography (HPLC) analysis, SF-2
was found to contain rutin, mangiferin and gallic acid (0.04%, 0.21% and 0.04%
respectively) in SF-2. This study supports the potential of use of Phaleria
macrocarpa extracts to treat hypertension in traditional medicine.
1CHAPTER 1
INTRODUCTION
1 Hypertension
1.1 Introduction to Hypertension
Hypertension is defined as sustained increase in the arterial blood pressure, owing
to a greater risk for cardiovascular diseases prevalent in advanced age (Awoke et
al., 2012; Brunton et al., 2007; Themistocles, 2007). Although systolic blood
pressure disproportionately rises greater in elders as a result of decreased
compliance in blood vessels caused by aging and arteriosclerosis, it is equally
affecting the health of middle-aged people where it has no apparent cause (Brunton
et al., 2007). Hypertension may manifest major risk for coronary artery disease,
myocardial infarction, cardiac failure and many other cardiovascular complications
(Awoke et al., 2012). It is a serious global health problem enticing the urge for
advanced research to ensure decrement of this fatal disease (Themistocles, 2007;
Tripathy, 2011). Physiologically normal blood pressure is considered to be within
the range of 120/80 mm Hg, the systolic and diastolic blood pressure respectively.
In hypertensive patients the hypertrophy and hyperplasia of arterial and ventricular
walls cause stiffness and reduced compliance, thus increasing the resistance to
blood flow which precede the onset of high blood pressure and other cardiovascular
health hazards (Fukutomi et al., 2010; Michael, 2001). With advanced age, lack of
elasticity and decreased compliance in arterial walls increase resistance to blood
2flow due to which heart has to pump hard to push blood through small arterioles to
maintain continuous and rhythmic contractions. When pressure in the arteries
remain high for longer period of time, it establishes a hypertensive state (Tripathy,
2011) common in elderly as well as young. Along with many others, cerebral stroke
is the highest risk as an outcome of sustained high blood pressure because of
inadequate blood flow in brain. Several factors contributing to the rise in blood
pressure include advancing age, life-style prone to develop high blood pressure,
chain smoking, metabolic syndrome as obesity, diabetes, renal function
abnormalities, various  structural changes as increased peripheral vascular
resistance or arterial rigidity (Koliaki et al., 2013). Generally life style
modifications such as regular exercise, maintenance of body weight, increased
water intake, alcohol and salt restriction as well to adapt the healthy dietary
patterns (Koliaki et al., 2013) can have a profound effect to lower blood pressure
(Michael, 2001).
Hypertension is considered to be the major risk factor for cardiovascular morbidity
and mortality (Katzung et al., 2009) including coronary heart disease, ischemia and
congestive heart failure etc. (Koliaki et al., 2013). On the basis of blood pressure,
there are four classes of blood pressure that are mentioned in Table 1.1 (Craig et al.,
2004).
31.2 Types of hypertension and its causes
Hypertension is a common disease with a wide range of causes. It’s a leading risk
factor for cardiovascular diseases worldwide, with a high morbidity, mortality and
considerable drug therapy (Agyemang et al., 2015; Santiago et al., 2014).
Hypertension has been divided into different types to seek its basic and underlying
effects to achieve proper health level.
Table 1.1 Classification of Blood Pressure (Katzung et al., 2009)
Blood Pressure Class
Systolic Pressure Diastolic Pressure
120 80 Normal
120-135 80-89 Pre-hypertension
140 90 Hypertension
140-159 90-99 Stage I
160 or above 100 Stage II
1.2.1 Essential/Primary Hypertension
Hypertension that has no specific cause is termed as essential, primary or idiopathic
hypertension (Katzung et al., 2009; Ritter et al., 2008) also commonly referred as
silent killer. It may go unnoticed for a long period of time or may exhibit its effects
in late age by producing cardiovascular disorders (Tripathy, 2011). Cardiac output
and peripheral vascular resistance are the primary determinants of essential blood
pressure. Increased peripheral resistance is attributed to combination of several
4abnormalities as genetic disposition, stress, environmental, dietary factors
(increased salt or decreased calcium and potassium intake) (Koliaki et al., 2013),
humoral abnormalities as hyperinsulinemia (Kahleová et al., 2002), natriuretic
hormone or renin-angiotensin-aldosterone system, increased production of
vasoconstrictor substances (angiotensin II and endothelin I) and decreased
production of vasodilating substances (prostacyclin, bradykinin, nitric oxide) in
vascular endothelium (Wells et al., 2011). Approximately 30% cases of essential
hypertension underlie the hereditary abnormalities as mutation of functional
abilities of certain genes as angiotensin, angiotensin converting enzyme (ACE),
beta-2 adrenoceptor and alpha-adducin. Life-style modifications, proper dietary
intake and reduced stress can help to treat these symptoms (Tripathy, 2011).
1.2.2 Secondary Hypertension
The hypertension that occurs because of a specific underlying cause is categorized
as secondary hypertension. In fact due to the underlying disorders as kidney failure,
tumors, thyroid problems, hyperaldosteronism, iatrogenic or drug-induced, birth
defect or  sleep apnea (Tripathy, 2011), Cushing’s disease (Barna et al., 2012;
Tripathy, 2011), contraction of aorta or renal artery etc., sometimes surgical
treatments are obligatory (Katzung et al., 2009). Pheochromocytoma is a tumor of
adrenal gland tissue that stimulates release of epinephrine and norepinephrine in
large amounts. Though low in prevalence (0-5%) it can give disastrous outcomes.
Chronic kidney diseases as renal artery stenosis (unilateral/bilateral) in which renal
artery gets narrow due to atherosclerosis may disrupt blood flow to target kidney
5creating hypertension. Cushing’s disease may be an underlying cause of persistent
hypertension as it exhibits vasoconstriction through hormonal effects.
1.2.3 Malignant Hypertension
Diastolic blood pressure that exceeds 130 mmHg gives rise to malignant state.
Target organs easily affected by malignant hypertension are kidney, heart and eyes
(retinopathy) raising the requirement of immediate medical attention (Roach et al.,
2006). Major symptoms include numbness of extremities, vision disturbance,
anxiety, fatigue and seizures. It can be regarded sometimes as a medical emergency
as stroke or suffocation can arise all of a sudden reaching to dangerous level. Blood
pressure rises quickly to a higher level sometimes without any previous signs and
symptoms creating urgency in the situation.
1.2.4 Isolated Systolic Hypertension
Consistent systolic blood pressure above 160mmHg and diastolic pressure below
90mmHg is considered as isolated systolic hypertension, a major health problem in
aging society (Wells et al., 2011). It occurs mostly in elderly people ≥ 60 years of
age (Brunton et al., 2007) and due to poor dietary intake. Age-related stiffness in
arteries and arteriosclerosis causing loss of elasticity in arteries give rise to isolated
systolic hypertension (Craig et al., 2004; Fukutomi et al., 2010). In young subjects
with elastic arteries, the arterial pulse pressure travels at a slow speed and returns in
the diastole of the cardiac cycle from the peripheral site. In older subjects, elastin
fibres are decreased and collagen fibres are increased, therefore the arteriolar walls
6are thickened and stiffened with loss of elasticity due to endothelial dysfunction and
vascular remodeling, thus the arterial wave travels faster and returns back in the late
systole thereby amplifying the systolic peak pressure and attenuating the diastolic
pressure consequently presenting the isolated systolic hypertension. Left ventricular
hypertrophy may develop due to increased arteriolar load as a result of isolated
systolic hypertension leading to cardiac failure. Cardiovascular morbidity and
mortality are more related to isolated systolic blood pressure than diastolic one
(Duprez, 2012).
1.2.5 White Coat Hypertension
It is also called anxiety-induced hypertension or isolated office hypertension
(Fukutomi et al., 2010). This type of hypertension only rises in doctor’s clinic and
remains normal outside the clinic prevalent in 30-40% of hypertensive subjects
(Pierdomenico et al., 2004). It is stress- related occurring in the vicinity of clinics
only, accounting to the clinical setting, increasing patient’s anxiety (Alper et al.,
1999). The difference between office blood pressure and daytime blood pressure is
known as white coat effect (WCE). Decreased arterial compliance with increased
wall stiffness in advanced age may be a profound risk factor for exaggerated blood
pressure in the proximity of a specific environment. Regular follow-ups to the clinic
may help to lower the chances to develop this hypertension (Wells et al., 2011).
71.2.6 Resistant Hypertension
Blood pressure systolic or diastolic, obstinately stagnant on 140/90 irrespective of
the triple-drug regime is considered resistant (Acelajado et al., 2012). At least four
medications are recommended for its treatment (Dudenbostel et al., 2012). Resistant
hypertension leads to refractory hypertension which remains uncontrolled even with
maximum drug therapy and needs special medical care, though its estimated
prevalence opts to be less than 5% of general population with high blood pressure
(Alper et al., 1999).  It needs ≥4 medication for treatment (Segura et al., 2010).
Patients with refractory hypertension are more prone to cardiovascular risk factors
than the patients with controlled hypertension (Sim et al., 2013) (Acelajado et al.,
2012). Obesity, excessive alcohol intake, excessive dietary salt intake and initially
mismanaged treatment of hypertension may give rise to resistant hypertension
(Ahmed et al., 2009). Non-compliance to treatment can also be a cause of resistant
hypertension. Few underlying causes and symptoms of secondary hypertension left
untreated or undiagnosed for a long period of time may result in the onset of stage
referred as resistant hypertension. Included in these may be obesity,
pheochromocytoma, chronic kidney diseases, primary aldosteronism and few
exogenous substances. Gain in weight leading to obesity gives rise to many health
complications including insulin resistance and hyperlipidemia. As obesity is
correlated to increase in blood pressure therefore it may create a hindrance in
treatment of blood pressure prompting to become resistant to therapy and develop
resistant hypertension. Stress- free and peaceful sleep is a blessing and an important
factor to restore blood pressure to its normal range (Ahmed et al., 2009).
8Obstructive sleep apnea (OSA) is a common symptom of patients with refractory
hypertension (Dudenbostel et al., 2012). Somehow obesity and OSA are correlated
with resistant hypertension. Obese patients have more visceral fat that stimulates
aldosterone secretion and increases adrenergic activation thereby disturbing sleep
cycle and increasing anxiety, thus contributing to resistant hypertension (Alper et
al., 1999). Pheochromocytoma is a tumor of adrenal gland tissue that stimulates
release of epinephrine and norepinephrine in large amounts. These are hormones
that contribute to increase in blood pressure and heart rate. Though low in
prevalence (0-5%) it can give disastrous outcomes. Chronic kidney diseases such as
renal artery stenosis (unilateral/bilateral) in which renal artery gets narrow due to
atherosclerosis may disrupt blood flow to target kidney creating hypertension and
making it resistant to treatment. Primary aldosteronism due to adrenal adenoma or
adrenal hyperplasia may be a profound obstruction in treatment of resistant
hypertension (Segura et al., 2010). Exogenous substances such as non-steroidal
anti-inflammatory drugs (NSAIDS), dietary salt, alcohol consumption, smoking
habits, nicotine or caffeine intake may play their role to resist treatment therapy of
hypertension. NSAIDS inhibit prostaglandins and thus vasodilation giving rise to
vasoconstriction as a secondary effect. Every cup of coffee provides an
augmentation of 0.8mmHg in systolic while 0.5mmHg in diastolic blood pressure
(Alper et al., 1999).
Patients with resistant hypertension should be encouraged to monitor blood pressure
daily and away from the vicinity of clinic to counteract the doubt of presence of
9white coat hypertensive effects if present. Discrepancy between home and clinic
readings should be assessed to start the antihypertensive therapy (Alper et al.,
1999).
1.3 Factors affecting the regulation of blood pressure
Normal pressure to maintain the flow of blood in a rhythmic manner throughout the
body is a necessary element of general physiology of our body. Increase in the
blood pressure (BP) either in elderly or young ones is a complex mechanism
influenced by genetic and environmental factors (Kahleová et al., 2002). Systolic
blood pressure is the pressure in heart to push oxygenated blood to whole system
and diastolic blood is the pressure under which heart relaxes and fills up the blood
under a normal physiological process. Whenever there is a rise or fall in blood
pressure due to any underlying reason or some environmental factor or advancing
age, the body has inbuilt ability to counteract the effect either increased or
decreased blood pressure to bring it back to its normal physiological state. This
ability is provided by different systems dominant in body which become active as
soon as any alarming signal goes to them indicating changes beyond the normal
range of blood pressure. The elasticity, compliance and capacity of vascular
components helps to regulate the flow of blood by three main  determinants i.e
blood volume, cardiac output (CO) and total peripheral resistance (TPR)
(Mannfred, 1997, 2003).
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Blood volume is determined by the rate at which blood flows in and out of vascular
compartment. Cardiac output is influenced by the rate at which blood is pumped
from heart to arteries and back to veins, both covering total blood flow. Venous
return is determined by TPR. Combined resistance in systemic circulation is
directly proportional to the rate at which blood leaves arteries and arterioles.= ×
Where BP stands for blood pressure, CO stands for cardiac output and TPR presents
total peripheral resistance (Tripathy, 2011).
Resistance (R) is inversely proportional to one fourth of the radius of lumen of
vessel. = −
Whereas F stands for “Flow of blood in circulatory system”,
Pa stands for “Pressure in arteries”
Pv stands for “Pressure in veins”, (Tripathy, 2011)
These all determinants working in a coordinated manner control and maintain
physiological homoeostasis, thus conducting the entire perfusion system properly.
Regulation of blood pressure is maintained by two major systems, remote control
system and local control system. These systems along with their division of classes
and subclasses are shown in Figure 1.1.
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1.3.1 Remote Control System
The system by name represents an automatically controlled system which is further
divided into two main classes as nervous system and humoral system.
1.3.1.1 Nervous System (NS)
Two divisions of autonomic nervous system that mainly control and regulate all
functions and responses of body from time to time are sympathetic nervous system
(SNS) and parasympathetic nervous system (PNS) (Brunton et al., 2007). SNS
innervate blood vessels primarily while heart is innervated by both SNS and PNS.
Nervous system possesses neural control or baroreflex system which regulates the
pressure of blood flow in the body.
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Figure 1.1 Factors regulating the blood pressure. Abbreviations NO: Nitric oxide; EDRF: Endothelium derived relaxing
factor; EDVCF: Endothelium derived vasoconstricting factor; EDHF: Endothelium derived hyperpolarizing factor;
TXA2: Thromboxane A2.
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1.3.1.2 Neural Control (Baroreflex System)
Baroreceptor reflex system has mechanosensitive receptors in aorta and carotid
sinus that give rise to afferent nerve fibre which relay impulses to central nervous
system (Katzung et al., 2009). A diagrammatic presentation of baroreflex system is
shown in Figure 1.2. Signals are being processed in central nervous system and
transmitted to heart and vasculature through efferent nerves conducting through
sympathetic and para sympathetic fibers. Contractile state of the vessels is being
regulated by sympathetic innervation in alpha-receptors of arterioles. Increased
sympathetic tone augments resistance in vessels thus enhancing blood pressure
causing vasoconstriction and vice versa (Richard et al., 2011). Sinoatrial node (SA)
of heart is being innervated by sympathetic (β1) and para sympathetic (vagal)
nervous system. Activation of sympathetic nerves in SA-node on one hand causes
positive chronotropic effect by increasing discharge rate of SA-pacemaker cells
thus enhancing heart rate and on the other hand leads to positive inotropic effect by
innervating β1-receptors on cardiac ventricles thus enhancing stroke volume.
Vagal innervation produces exactly opposite effect thus lowering conduction
velocity and heart rate. Similarly increase in blood pressure activates baroreceptor
activity leading to inhibition of sympathetic impulses resulting in vasorelaxation
through effect on blood vessels and decreased contractility and heart rate through
effect on heart, while parasympathetic impulses are enhanced inferring decreased
heart rate and contractility (Craig et al., 2004; Mannfred, 1997, 2003).
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Figure 1.2 Presentation of baroreflex system. Adopted from Basic and clinical pharmacology (Katzung et al., 2009).
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1.3.1.2.a Vasomotor Fibres and Vasomotor Centre
Vasomotor center is located in reticular substance of medulla and lower third of
pons. It transmits parasympathetic impulses through vagus nerve to heart and
sympathetic impulses through spinal cord. It contains several important centers,
vasoconstrictor area, vasodilator area and sensory area. The vasoconstrictor area
distributes its fibres to all levels of spinal cord to excite vasoconstrictor neurons of
sympathetic nervous system. The fibres from the neurons of vasodilator area project
upward to vasoconstrictor area and causes vasodilation. The sensory area controls
activities of both vasoconstrictor and vasodilator areas, for example baroreceptor
reflex controlling blood pressure (Tripathy, 2011).
1.3.1.2.b Pressoreceptors
An acute control and regulation of BP is nicely undertaken by pressoreceptors or
baroreceptors present in large arteries of thorax, neck, carotid and aortic sinuses. If
arterial pressure rises, the afferent impulses from pressoreceptors decrease heart
rate and cardiac contractility by modulating cardiac inhibitory center, turning down
the mean arterial pressure (MAP) and activating low pressure receptors (Rau et al.,
2001). These low pressure receptors activate rostral ventrolateral medulla (RVLM)
or medulla pressor which stimulates SNS to release NE, with ultimate effect of
increasing blood pressure to normal physiological level (Tripathy, 2011).
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1.3.1.2.c Chemoreceptors
The chemoreceptors play their part in BP regulation during respiration giving
response to changes in chemical constituents of blood. They are found in aortic arch
and in large arteries of neck. Peripheral chemoreceptors in carotid bodies respond to
hypoxia whereas central ones located on medulla and brainstem respond to
hypercapnia (Pitsikoulis et al., 2008). If oxygen content of blood is decreased and
hydrogen ion level is increased, then it is being sensed immediately by
chemoreceptors and impulse is sent to vasomotor center though vasomotor fibres.
Ultimately BP is increased by vasoconstriction effect (Tripathy, 2011).
1.3.1.2.d Higher Brain Centers
Higher brain centers include hypothalamus and cortex. Fight or flight situation
stimulates higher brain centers to relay information to medullary center. Medullary
center contains reflexes to control BP, so it regulates either fall or rise in BP. Any
changes in blood pressure detected by stretch receptors in aortic and carotid bodies
influence medullary centre to send nerve impulses through sympathetic fibres either
to sinoatrial node to enhance cardiac muscle contraction or to vagus nerve to lessen
and slow down cardiac muscle contraction. It also helps to increase stroke volume
of heart to regulate cardiac output thus blood pressure (O'Donohoe et al., 2013).
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1.3.1.3 Humoral System
It controls and regulates blood pressure by modulating chemical stimuli and renal
response causing vasodilation, vasoconstriction, release of chemicals and hormones
and creating alteration of blood volume.
1.3.1.3.a Chemical Controls
Chemicals such as epinephrine, norepinephrine, atrial natriuretic peptide (ANP) and
arginine vasopressin control and regulate BP on short term basis. They act directly
on VSMC or vasomotor center to alter BP.
1.3.1.3.b Adrenal Medulla Hormones
Epinephrine and norepinephrine are catecholamines secreted by adrenal medulla in
response to stress or excitement. These bind to adrenergic receptors present on
target cells such as heart and blood vessels to give positive chronotropic, inotropic
effects and vasoconstricting effects respectively (Tripathy, 2011).
1.3.1.3.c The Peptide Hormones
1.3.1.3.c.i Atrial Natriuretic Peptide (ANP)
It is a powerful vasodilator with a short half -life. It is secreted from myocytes of
atria when high blood pressure is detected by stretch receptors as a result of
increased venous return (O'Donohoe et al., 2013). ANP binds to choroid plexus of
epithelial cells and generates cyclic guanosine monophosphate causing alteration in
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ion transport thus slowing cerebrospinal fluid production (Johanson et al., 2006).
Antagonizing the effect of catecholamines it reduces blood volume by increasing
renal sodium and water clearance.
1.3.1.3.c.ii Antidiuretic Hormone (ADH)
Antidiuretic peptide hormone also known as arginine vasopressin (AVP) acts on V1
receptors in VSMC and V2 receptors on renal collecting duct. It is released in
response to hypovolemic shock. ADH increases water permeability through cAMP-
dependent pathway and decreases urine formation. This effect increases blood
volume, CO and arterial pressure. ADH causes vasoconstriction via IP3 –signal
transduction pathway and results in increased arterial pressure as well as peripheral
vascular resistance (PVR). Its levels in blood increases fivefold in hypovolemic
shock and it exerts its pressor effect by stimulating V2 receptors (Johanson et al.,
2006).
1.3.1.3.d Ouabain and Dihydro-ouabain Like Factors
Endogenous ouabain (11-epimer) of plant ouabain and dihydro-ouabain were
discovered in 1991. They are synthesized by adrenal cortex and inhibit sodium-
pump (Na-K-ATPase) in cell membrane, thereby increasing sodium level and
vascular tone (Schoner et al., 2005). During essential hypertension they induce
natriuresis to lower down blood volume and ultimately decrease blood pressure
(Tripathy, 2011).
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1.3.1.3.e Renin Regulation
Kidney is a vital organ of our body which is involved in the maintenance of normal
blood pressure through interference in the total blood volume in body fluids. It
regulates blood pressure in long term manner by keeping in control the blood
volume by two parameters i.e. the renin-angiotensin-aldosterone system and the
kallikerin-kallidin system (Katzung et al., 2009).
1.3.1.3.f Renin-angiotensin-aldosterone system (RAAS)
The direct role of RAAS is to increase blood pressure on long term basis (Richard
et al., 2011). Renin is a hormone that is released by the kidney into systemic
circulation. Angiotensin-I is formed by action of renin on angiotensinogen (an α-2
globulin). Inactive angiotensin-I is converted to active angiotensin-II which is a
potent vasoconstrictor and is a major octapeptide hormone of RAAS. It acts on
AT1-receptors of vasculature and also secrete aldosterone from medullary cortex
(Ritter et al., 2008). Both of these actions help to increase blood pressure. Indirectly
in baroreceptor reflex action, during SNS- activation, angiotensin-II increases
sympathetic outflow and increases heart rate and blood pressure. RAAS-pathway
blockade serves consequential improvement in cardiovascular health by reduction
in BP and restoration of normal endothelial and renal function.
1.3.1.3.g Kallikrein-kallidin System (KKS)
Bradykinin is an important inflammatory mediator involved in the maintenance of
normal cardiovascular function. It is formed from high molecular weight kininogen
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by plasma kallikerin. Bradykinin induces increased intracellular calcium
concentrations that activates intracellular cytosolic phospholipase A2. Combined
actions of phospholipase A2, cyclooxygenase and prostaglandin synthases produce
prostaglandins such as PGE2 which induces vasodilation and inhibits smooth
muscle cell proliferation (Bradbury et al., 2004). Bradykinin augments nitric oxide
(NO) and prostacyclin generation to improve endothelial dysfunction. Kallidin is
released from kininogens from tissue kallikrein (Tripathy, 2011).
1.3.2 Local Control System
Vascular perfusion pressure is maintained by a regulated flow of blood in tissues or
in regional vascular beds. Two most prominent pillars of this system are myogenic
control and metabolic control.
1.3.2.1 Myogenic Control
Smooth muscles contribute to the structure of walls of arteries, arterioles, veins and
venules. Circulating hormones and mediators released locally from endothelial cells
and sympathetic nerve terminals control the contractile state of vessels by
regulating the amount of calcium in smooth muscle cells (Rang et al., 2011). Rise in
calcium (Ca2+ ) initiates contraction in smooth muscle cells which either activates
myosin light-chain kinase causing myosin phosphorylation or inhibits myosin
phosphatase to sensitize myofilaments to Ca2+ (Ritter et al., 2008).
Contraction of smooth muscle cells is excited by three mechanisms through agents
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a) Inositol triphosphate causes release of intracellular calcium causing
contraction.
b) Membrane depolarization opens the voltage-gated calcium channels
increasing entry of calcium thus causing contraction.
c) Increasing sensitivity to Ca2+ by myosin light-chain kinase.
Relaxation can be caused by these three mechanisms
a) Direct inhibition of voltage-gated calcium channels
b) Indirectly by membrane hyperpolarization
c) Increased intracellular cyclic guanosine monophosphate (cGMP) or
cyclic adenosine monophosphate (cAMP) which  either opposes agonist-
induced increase in Ca2+ or inactivates myosin light-chain kinase
facilitating Ca2+-efflux thus causing relaxation.
Tissues of arteries and veins self-regulate and accommodate to changes in pressure
with which blood enters, its flow pattern and the level of resistance present. Due to
such adjustment phases systemic blood pressure and tissue perfusion are maintained
and regulated by myogenic control.
1.3.2.1.a Endothelium Derived Vasodilators
A passive barrier between plasma and extracellular fluid lining the innermost layer
of blood vessels is the vascular endothelium (Tripathy, 2011) which is also a source
of several potent mediators that control the contractile and dilator tone of
underlying smooth muscles (Ritter et al., 2008; Spieker et al., 2000). It plays a
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crucial role to control hypertension (Spieker et al., 2000). These mediators include
the followings:
1.3.2.1.a.i Prostacyclin
Prostacyclins (PGI2) is a member of eicosanoid family (Ritter et al., 2008). It acts
on prostanoid receptors and relax smooth muscles (Tripathy, 2011). PGI2 is
synthesized from COX by arachidonic acid in response to shear stress (Spieker et
al., 2000). It increases the level of cGMP  by binding with G- protein coupled
receptors, through protein kinase A activation it phosphorylates few proteins which
help to relax vascular smooth muscle cells by inhibiting myosin light chain kinase
(Ritter et al., 2008). PGI2 also inhibit platelet aggregation by activating adenylyl
cyclase and inhibits the increase in intracellular level of calcium in smooth muscle
cells. Dynamic balance between endothelial dilators and constrictors is disrupted
during cardiovascular disease states. Bioactivity of NO or PGI2 decreases in
endothelial dysfunction and activity of contractile factors increase. PGE2 is
synthesized by microvessels of endothelial cells which either act as direct
vasodilators or inhibit norepinephrine (NE) release from sympathetic nerve
terminals. PGG2 or PGH2 are also known as prostaglandin endoperoxide
intermediates. These are contracting factors which are derived from endothelium
and act via thromboxane receptors.
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1.3.2.1.a.ii Nitric oxide (NO)
Nitric oxide, previously known as endothelium-derived relaxing factor is an
endothelium derived vasodilator (Spieker et al., 2000). Nitric oxide synthase (NOS)
in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) and
tetrahydrobioptin (BH4) synthesizes NO from L-arginine. Of all the three types
discovered, the endothelial NOS (eNOS) and neuronal NOS (nNOS) are vascular
endothelial types and need calcium for their activation. The third type, inducible
NOS (iNOS) is not calcium dependent and inflammation stimuli trigger its
formation. NO is synthesized by eNOS present in vascular endothelial cells. It is
released from endothelium in the vascular lumen from where it binds to heme
moiety of soluble guanylate cyclase (sGC) in adjacent VSMC. This action increases
formation of cGMP. cGMP is a phosphate stimulating phosphorylation of several
cellular proteins which exhibits vasodilation and relax in VSMC. Endothelial
dysfunction is a major problem in essential hypertension due to which NO level in
these patients is decreased to a significant amount. It can lower down the blood
pressure caused by effects of NA, serotonin, endothelin or angiotensin-II. Its
continuous release in vessels causes vascular relaxation thus controlling blood
pressure physiologically, (Ritter et al., 2008) as well it inhibits vascular smooth
muscle proliferation, platelet aggregation, monocyte adhesion (Tripathy, 2011) and
migration thus preventing atherosclerosis and thrombosis.
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1.3.2.1.a.iii Endothelium-derived hyperpolarizing factors (EDHFs)
Generally NO and PGI2 hyperpolarize smooth muscle cells due to their relaxant
effects (Spieker et al., 2000). Even if synthesis of NO and PGI2 is inhibited,
endothelium-dependent relaxation persists in some vessels in response to few
mediators as acetylcholine (Ach) or bradykinin, this dilatation effect can be
attributed to EDHFs. These include epoxyeicosatrienoic acids (EETs-derived from
cytochrome P450 enzymes), hydrogen peroxide (H2O2), carbon monoxide (CO), C-
type natriuretic peptide (CNP), few lipoxygenase (LOX) products and calcium-
activated potassium channels (Tripathy, 2011).
1.3.2.1.b Endothelium Derived Vasoconstrictor Factors (EDCFs)
Diseased state of the body imbalances the normal ratio of contractile and dilatory
mediators released by endothelium. The production of NO is decreased in a
distinguishable amount that pushes the contractile mediators to come in action and
give vasoconstricting effect in VSMC and thus serves to augment BP.
1.3.2.1.b.i Endothelin
Endothelin (ET) is abundantly found in most of the vascular tissues. Isomers of
endothelin are ET-1, ET-2 and ET-3. Physiologically it is a regulator of blood
pressure but during pathological conditions ET constricts blood vessels
predominantly. It has two types of receptors named ETA and ETB . ETA-receptors
couple with phospholipase-C(PLC), protein kinase-C(PK-C) and causes
mitogenesis as well as aldosterone secretion and release of intracellular Ca2+
